Eclipse Regenesis

Pioneering regenerative therapy for Short Bowel Syndrome (SBS) with the first device designed to stimulate new intestinal growth.

health AI/medtech/regenerative medicine (gastrointestinal/regenerative device)

Visit website LinkedIn ↗

Raised$2.93M

Founded2017

Employees5

LocationMenlo Park, CA

Business modelB2B/B2C with healthcare partners and clinicians (device-based therapy; partnerships with major hospitals)

About

The first tissue regeneration therapy for Short Bowel Syndrome (SBS). SBS is a devastating condition where the small intestine is too short to absorb sufficient nutrients to sustain a patient. It results from the surgical removal of a large portion of the small intestine due to a congenital or acquired defect. The Eclipse XL1 therapy is designed to grow 2-3x longer, healthy intestine within 2-3 weeks using an entirely mechanical, repeatable approach. The new tissue has been shown to absorb nutrients and function the same as, or better than, healthy intestinal tissue. The Eclipse XL 1 device is an investigational product and limited by Federal law to investigational use. It is not currently available for commercial sale in the U.S. or any other region. Eclipse Regenesis and Eclipse XL1 are registered trademarks of Eclipse Regenesis, Inc.

Product

Value proposition: Device-based regenerative therapy to stimulate growth of healthy intestinal tissue, potentially reducing dependence on parenteral nutrition and invasive treatments.
Target customers: Clinicians, healthcare systems, research institutions, investors/families seeking SBS options

Founders

Andre Bessette — CEO, Co-Founder
James Dunn — Co-Founder
Tom Krummel — Co-Founder and Chairman
Eric Kramer — Engineer, Co-Founder

Products

Eclipse XL1 device (first device-based regenerative therapy for SBS)

Key features

Stimulates new intestinal tissue growthUses patient’s own biology to regenerate tissueNon-pharmacologic device-based therapy

Technologies

Regenerative medicineImplantable/assistive deviceTissue growth stimulation

Target conditions

Short Bowel Syndrome (SBS)

Care settings

hospitalclinicresearch setting

Partnerships

Boston Children’s HospitalCincinnati Children’sUCLA HealthStanford Medicine

Traction metrics

device-based therapy milestone for SBSpartnerships with leading healthcare organizations

Investors

National Science FoundationNational Institutes of Health (NIH)MedTech InnovatorWest Coast Consortium for Technology & Innovation in PediatricsAtacama VenturesHHSAmerica’s Seed Fund

News

Breakthroughs in Regenerative GI Therapy - Eclipse Regenesis · 2025-09-25T00:00:00.000Z
Medtech Startup Eclipse Regenesis Offers Hope to Young Patient with Short Bowel Syndrome - Fogarty Innovation · 2024-12-11T15:53:45.000Z
Every Centimeter Counts: Eclipse Regenesis Gives Toddler with SBS a Second Chance - Fogarty Innovation · 2025-10-08T00:35:10.000Z
Every Centimeter Counts: Eclipse Regenesis Gives Toddler with SBS a Second Chance - MedTech Innovator · 2025-10-07T21:05:52.000Z
In pursuit of a medical device for children with short gut syndrome · 2026-02-25T00:00:00.000Z
Andre Bessette's Post - LinkedIn · 2025-09-29T00:00:00.000Z

Browse similar startups

Related startups

Elenae Therapeutics, Inc. — Berkeley, CA
Elomia Health — San Francisco, CA
Emerald Care Home — Dublin, CA
Endo Health (a16z SR) — San Francisco, CA
Evercrisp Biosciences — Berkeley, CA
EXCEL MEDICAL BILLING, INC. — Los Angeles, CA
Health Data Max LLC — Arlington, VA
Johnson Medtech — Vandalia, OH
Just Vital Solutions PLLC (Remote Patient Monitoring) — Houston, TX
Limber Health — Pittsburgh, PA
Magpie MedTech Ventures — Providence, RI
MDC Studio — Baltimore, MD

Profile updated Jul 29, 2026. Sources: eclipseregenesis.com